Kyntra Bio, Inc. · NASDAQ:KYNB
Kyntra Bio — FibroGen — Merger or Acquisition (February 2025)
10 slides from Kyntra Bio's merger presentation, Feb 20, 2025
Slide 1: FibroGen China Sale Presentation
FibroGen China Sale Presentation February 20, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its collaboration partners Fortis and UCSF. These forward-looking stat
Slide 3: Completing FibroGen Transformation: Delivering on 2025 Strategic Priorities
Completing FibroGen Transformation: Delivering on 2025 Strategic Priorities 1 2 3 Simplify Operations and Advance FG-3246 and Evaluate Development Pathway Balance Sheet FG-3180 Development Program for Roxadustat in LR-MDS • Sale of FibroGen China simplifies • Initiation of Phase 2 monotherapy study
Slide 4: FibroGen China Sale: Summary of Key Commercial Terms
FibroGen China Sale: Summary of Key Commercial Terms Purchase Price ◼ Enterprise value of $85 million Value of ◼ Approximately $75 million of FibroGen net cash held in China at closing FibroGen Cash o Defined as net cash at closing held by FibroGen China, including FibroGen’s portion of Falikang net
Slide 5: FG-3246 and FG-3180 Present a Unique Opportunity in mCRPC
FG-3246 and FG-3180 Present a Unique Opportunity in mCRPC Novel Mechanism of Action and Potential Compelling Results in Two Phase 1 Studies First-in-Class Opportunity FG-3246 was clinically active as monotherapy Binds to a unique epitope on CD46 present on and in combination with enzalutamide cancer
Slide 6: FG-3246 and FG-3180 Phase 2 Monotherapy Design Highlights
FG-3246 and FG-3180 Phase 2 Monotherapy Design Highlights Phase 2 monotherapy trial initiation is expected in 2Q 2025 Phase 2 - FG-3246 Dose Optimization in Post-ARSI, Pre-Chemo mCRPC, All Comers (US only) Primary Endpoint: Optimal dose for Phase 3 based on efficacy, safety, and PK Secondary Endpoin
Slide 7: FG-3246 and FG-3180 Near-Term Development Highlights
FG-3246 and FG-3180 Near-Term Development Highlights Development Strategy Provide Significant Optionality in Prostate Cancer Alone …unlocks multiple registrational pathways sequentially or in parallel Robust Phase 2 monotherapy • Multiple lines of therapy in prostate cancer trial in pre-chemo mCRPC…
Slide 8: Significant Opportunity for Roxadustat in Anemia Associated with LR-MDS
Significant Opportunity for Roxadustat in Anemia Associated with LR-MDS ✓ Targeted Phase 3 program could enable an approval ✓ Significant unmet need despite recent approvals in anemia associated with Lower-Risk MDS ✓ No other oral treatments for anemia of LR-MDS ✓ FDA Orphan designation would provid
Slide 9: Completing FibroGen Transformation: Delivering on 2025 Strategic Priorities
Completing FibroGen Transformation: Delivering on 2025 Strategic Priorities 1 2 3 Simplify Operations and Advance FG-3246 and Evaluate Development Pathway Balance Sheet FG-3180 Development Program for Roxadustat in LR-MDS • Sale of FibroGen China simplifies • Initiation of Phase 2 monotherapy study
Slide 10: Thank You
Thank You For more information contact ir@fibrogen.com NASDAQ: FGEN